Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Proton pump inhibitors (PPIs) use may be associated with nephritis and acute renal injury. The risk of PPIs and deterioration of renal function, in patients with renal diseases, needs to be investigated. A case-control study was conducted in a nation-wide data setting from the Taiwan National Health Insurance Research Database (NHIRD). This case-control study used data extracted from NHIRD between the years 2006 and 2011. We used propensity scores to match 3808 patients suffering from renal diseases (ICD-9-CM codes 580-589), with patients (aged ≥20 years) who had had a recent diagnosis of end-stage renal diseases (ESRDs) and had undertaken renal replacement therapy during the period of 2006 to 2011. The 3808 control subjects were selected from people who had a history of renal diseases, but no ESRD. The risk of ESRD in patients with renal diseases and PPIs use was estimated by using odds ratios (ORs) and 95% confidence intervals (CI). The use of a PPIs was associated with a significantly higher risk of ESRD (adjusted OR = 1.88, 95% CI = 1.71-2.06) in renal disease patients. Of all the types of PPI combined, the adjusted OR was 1.92 (95% CI = 1.74-2.13) for those on <100 cumulative DDD and was 1.74-fold (95% CI = 1.52-2.00) for those on ≥100 cumulative DDD. PPIs use is associated with the risk of ESRD in patients with renal diseases. It is necessary that appropriate prescription of PPIs coordinated with the close monitoring renal function of patients diagnosed with renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-induced acute interstitial nephritis
Perazella, M. A., & Markowitz, G. S. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.71 · Cited by 378
Proton Pump Inhibitors and Acute Interstitial Nephritis
Geevasinga, N., Coleman, P. L., Webster, A. C., & Roger, S. D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.11.004 · Cited by 188
Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
Cunningham, J., Rodriguez, M., & Messa, P. (2012) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfr166 · Cited by 188
Cited by
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Kukova, L., Obeid, W., Luciano, R., Kuperman, M., Moeckel, G. W., Kashgarian, M., Perazella, M. A., Cantley, L. G., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa169 · Cited by 47
Miao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
“…that PPI use increased the risk of ESKD by 88%, with the highest adjusted OR of esomeprazole (1.69; 95% CI, 1.45–1.98) and pantoprazole (1.63; 95% CI, 1.39–1.90), followed by rabeprazole (1.36; 95% CI, 1.02–1.81), lansoprazole (1.23; 95% CI, 1.09–1.4), and omeprazole (1.14; 95% CI, 1.02–1.26) [87].”
BackgroundInfluential
Metadata
- Authors
- Peng, Y.-C., Lin, C.-L., Yeh, H.-Z., Chang, C.-S., Wu, Y.-L., & Kao, C.-H.
- Venue
- Medicine
- Published
- 2016-04
- Volume
- 95
- Issue
- 15
- Pages
- e3363
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2346270485
- Cited by
- 55
- References
- 3
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. https://app.cochat.ai/papers/10.1097/md.0000000000003363
- The paper
- Peng, Y.-C., Lin, C.-L., Yeh, H.-Z., Chang, C.-S., Wu, Y.-L., & Kao, C.-H. (2016). Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. Medicine. https://doi.org/10.1097/md.0000000000003363
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.